tbuckley/cabot-search huggingface dataset:
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Authors: Judith L. Heidebrink, Henry L. Paulson
Journal: Annual Review of Medicine (2024)

When the US Food and Drug Administration used the accelerated approval process to authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD), many people hoped this signaled a new era of disease-modifying treatment. But 2 years later, aducanumab's failure to launch provides a cautionary tale about the complexities of dementia and the need for a thorough and transparent review of the role that regulatory agencies and various stakeholders play in approving AD drugs. We highlight the events leading to aducanumab's controversial approval and discuss some of the key lessons learned from the drug's failure to deliver the hoped-for benefits. These lessons include the inherent limitations of antiamyloid strategies for a complex disease in which amyloid is only one of several pathological processes, the need for clinical trials that better reflect the diversity of communities affected by AD, the potential pitfalls of futility analyses in clinical trials, the need for greater transparency and other modifications to the approval process, and the dementia field's unreadiness to move from the highly controlled environment of clinical trials to the widespread and chronic use of resource-intensive, disease-modifying drugs in real-world treatment scenarios. People with dementia desperately need effective therapies. We hope that the aducanumab story will inspire changes to the approval process—changes that restore public trust and improve future efforts to deliver disease-modifying therapies to the clinic.
Exploring Adaptive Phenotypes for the Human Calcium-Sensing Receptor Polymorphism R990G
Authors: Barbara Sinigaglia, Jorge Escudero, Simone A Biagini, Jorge Garcia-Calleja, Josep Moreno, Begoña Dobon, Sandra Acosta, Mayukh Mondal, Sandra Walsh, Gabriela Aguileta, Mònica Vallès, Stephen Forrow, Juan Martin-Caballero, Andrea Bamberg Migliano, Jaume Bertranpetit, Francisco J Muñoz, Elena Bosch
Journal: Molecular Biology and Evolution (2024)

Abstract Rainforest hunter–gatherers from Southeast Asia are characterized by specific morphological features including a particularly dark skin color (D), short stature (S), woolly hair (W), and the presence of steatopygia (S)—fat accumulation localized in the hips (DSWS phenotype). Based on previous evidence in the Andamanese population, we first characterized signatures of adaptive natural selection around the calcium-sensing receptor gene in Southeast Asian rainforest groups presenting the DSWS phenotype and identified the R990G substitution (rs1042636) as a putative adaptive variant for experimental follow-up. Although the calcium-sensing receptor has a critical role in calcium homeostasis by directly regulating the parathyroid hormone secretion, it is expressed in different tissues and has been described to be involved in many biological functions. Previous works have also characterized the R990G substitution as an activating polymorphism of the calcium-sensing receptor associated with hypocalcemia. Therefore, we generated a knock-in mouse for this substitution and investigated organismal phenotypes that could have become adaptive in rainforest hunter–gatherers from Southeast Asia. Interestingly, we found that mouse homozygous for the derived allele show not only lower serum calcium concentration but also greater body weight and fat accumulation, probably because of enhanced preadipocyte differentiation and lipolysis impairment resulting from the calcium-sensing receptor activation mediated by R990G. We speculate that such differential features in humans could have facilitated the survival of hunter–gatherer groups during periods of nutritional stress in the challenging conditions of the Southeast Asian tropical rainforests.
COPD basal cells are primed towards secretory to multiciliated cell imbalance driving increased resilience to environmental stressors
Authors: Mircea Gabriel Stoleriu, Meshal Ansari, Maximilian Strunz, Andrea Schamberger, Motaharehsadat Heydarian, Yaobo Ding, Carola Voss, Juliane Josephine Schneider, Michael Gerckens, Gerald Burgstaller, Alejandra Castelblanco, Teresa Kauke, Jan Fertmann, Christian Schneider, Juergen Behr, Michael Lindner, Elvira Stacher-Priehse, Martin Irmler, Johannes Beckers, Oliver Eickelberg, Benjamin Schubert, Stefanie M Hauck, Otmar Schmid, Rudolf A Hatz, Tobias Stoeger, Herbert B Schiller, Anne Hilgendorff
Journal: Thorax (2024)

Introduction Environmental pollutants injure the mucociliary elevator, thereby provoking disease progression in chronic obstructive pulmonary disease (COPD). Epithelial resilience mechanisms to environmental nanoparticles in health and disease are poorly characterised. Methods We delineated the impact of prevalent pollutants such as carbon and zinc oxide nanoparticles, on cellular function and progeny in primary human bronchial epithelial cells (pHBECs) from end-stage COPD (COPD-IV, n=4), early disease (COPD-II, n=3) and pulmonary healthy individuals (n=4). After nanoparticle exposure of pHBECs at air–liquid interface, cell cultures were characterised by functional assays, transcriptome and protein analysis, complemented by single-cell analysis in serial samples of pHBEC cultures focusing on basal cell differentiation. Results COPD-IV was characterised by a prosecretory phenotype (twofold increase in MUC5AC + ) at the expense of the multiciliated epithelium (threefold reduction in Ac-Tub + ), resulting in an increased resilience towards particle-induced cell damage (fivefold reduction in transepithelial electrical resistance), as exemplified by environmentally abundant doses of zinc oxide nanoparticles. Exposure of COPD-II cultures to cigarette smoke extract provoked the COPD-IV characteristic, prosecretory phenotype. Time-resolved single-cell transcriptomics revealed an underlying COPD-IV unique basal cell state characterised by a twofold increase in KRT5 + ( P =0.018) and LAMB3 + ( P =0.050) expression, as well as a significant activation of Wnt-specific ( P =0.014) and Notch-specific ( P =0.021) genes, especially in precursors of suprabasal and secretory cells. Conclusion We identified COPD stage-specific gene alterations in basal cells that affect the cellular composition of the bronchial elevator and may control disease-specific epithelial resilience mechanisms in response to environmental nanoparticles. The identified phenomena likely inform treatment and prevention strategies.
Analytical challenges in omics research on asthma and allergy: A National Institute of Allergy and Infectious Diseases workshop
Authors: Supinda Bunyavanich, Patrice M. Becker, Matthew C. Altman, Jessica Lasky-Su, Carole Ober, Karsten Zengler, Evgeny Berdyshev, Richard Bonneau, Talal Chatila, Nilanjan Chatterjee, Kian Fan Chung, Colleen Cutcliffe, Wendy Davidson, Gang Dong, Gang Fang, Patricia Fulkerson, Blanca E. Himes, Liming Liang, Rasika A. Mathias, Shuji Ogino, Joseph Petrosino, Nathan D. Price, Eric Schadt, James Schofield, Max A. Seibold, Hanno Steen, Lisa Wheatley, Hongmei Zhang, Alkis Togias, Kohei Hasegawa
Journal: Journal of Allergy and Clinical Immunology (2024)
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Authors: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, J. Connor Wells, Renee Maria Saliby, Talal El Zarif, Chris Labaki, Naveen S. Basappa, Bernadett Szabados, Thomas Powles, Ian D. Davis, Lori A. Wood, Aly-Khan A. Lalani, Rana R. McKay, Jae-Lyun Lee, Luis Meza, Sumanta K. Pal, Frede Donskov, Takeshi Yuasa, Benoit Beuselinck, Georges Gebrael, Neeraj Agarwal, Toni K. Choueiri, Daniel Y.C. Heng
Journal: European Urology (2024)

Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated with longer median overall survival (OS; 32.7 mo, 95% confidence interval [CI] 22.3-not reached) versus tyrosine kinase inhibitor monotherapy (20.6 mo, 95% CI 15.7-24.5; p = 0.019), as were intensive focal therapies with stereotactic radiotherapy or neurosurgery (31.4 mo, 95% CI 22.3-37.5) versus whole-brain radiotherapy alone or no focal therapy (16.5 mo, 95% CI 10.2-21.1; p = 0.028). On multivariable analysis, IO-based regimens (HR 0.49, 95% CI 0.25-0.97; p = 0.040) and stereotactic radiotherapy or neurosurgery (HR 0.48, 95% CI 0.29-0.78; p = 0.003) were independently associated with longer OS, as was IMDC favorable or intermediate risk (HR 0.40, 95% CI 0.24-0.66; p < 0.001). Intensive systemic and focal therapies were associated with better prognosis in this population. Further studies should explore the clinical effectiveness of multimodal strategies. PATIENT SUMMARY: In a large group of patients with advanced kidney cancer, we found that 8.1% had brain metastases when starting systemic therapy. Patients with brain metastases had significantly poorer prognosis than those without brain metastases. Receipt of combination immunotherapy, stereotactic radiotherapy, or neurosurgery was associated with longer overall survival.
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)
Authors: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, Tristan R. Grogan, David Elashoff, Ethan C. Lam, Kevyn J. Clark, Michael L. Steinberg, Wolfgang P. Fendler, Thomas A. Hope, Nicholas G. Nickols, Johannes Czernin, Jeremie Calais
Journal: European Urology (2024)
Thulium Fiber Laser Versus Holmium:Yttrium Aluminum Garnet for Lithotripsy: A Systematic Review and Meta-analysis
Authors: Alessandro Uleri, Alba Farré, Paula Izquierdo, Oriol Angerri, Andrés Kanashiro, Josep Balaña, Vineet Gauhar, Daniele Castellani, Francisco Sanchez-Martin, Manoj Monga, Adolfo Serrano, Mantu Gupta, Michael Baboudjian, Andrea Gallioli, Alberto Breda, Esteban Emiliani
Journal: European Urology (2024)
Benefits and opportunities of the transgenic Oncopig cancer model
Authors: Kirtan Joshi, Bhanu P. Telugu, Randall S. Prather, Jeffrey N. Bryan, Timothy J. Hoffman, Jussuf T. Kaifi, Satyanarayana Rachagani
Journal: Trends in cancer (2024)

Cancer remains a leading cause of morbidity and mortality, and a paradigm shift is needed to fundamentally revisit drug development efforts. Pigs share close similarities to humans and may serve as an alternative model. Recently, a transgenic 'Oncopig' line has been generated to induce solid tumors with organ specificity, opening the potential of Oncopigs as a platform for developing novel therapeutic regimens.
Bangladesh eliminates visceral leishmaniasis
Authors: Nazia Nagi
Journal: The Lancet Microbe (2024)

On Oct 31, 2023, WHO announced that Bangladesh has eliminated visceral leishmaniasis (also known as kala-azar) as a public health problem, the first country worldwide to do so. This elimination status was validated by WHO after Bangladesh reported less than 1 cases per 10 000 people in the previous 3 consecutive years. In 2022, Bangladesh reported only 47 kala-azar cases, and the WHO South-East Asia Region reported 1069 cases, the lowest number recorded.
US workers during the covid-19 pandemic: uneven risks, inadequate protections, and predictable consequences
Authors: David Michaels, Emily A Spieler, Gregory R Wagner
Journal: BMJ (2024)

<b>David Michaels</b>, <b>Emily A Spieler</b>, and <b>Gregory R Wagner</b> consider how covid-19 affected frontline workers in the US and what needs to be done to ensure they are better protected in future
Trends in COVID-19 admissions and deaths among people living with HIV in South Africa: analysis of national surveillance data
Authors: Waasila Jassat, Caroline Mudara, Lovelyn Ozougwu, Richard Welch, Tracy Arendse, Maureen Masha, Lucille Blumberg, Tendesayi Kufa, Adrian Puren, Michelle Groome, Nevashan Govender, Pedro Pisa, Sharlene Govender, Ian Sanne, Heena Brahmbhatt, Lauren Parmley, Milani Wolmarans, Petro Rousseau, Anthony Selikow, Melissa Burgess, Lauren Hankel, Arifa Parker, Cheryl Cohen
Journal: The Lancet HIV (2024)
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
Authors: Elisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, Stephan Mathas, Friederike Braulke, Gerlinde Egerer, Alexander Röth, Simon Schliffke, Peter Borchmann, Uta Brunnberg, Frank Kroschinsky, Robert Möhle, Andreas Rank, Dominique Wellnitz, Benjamin Kasenda, Lisa Pospiech, Julia Wendler, Florian Scherer, Martina Deckert, Elina Henkes, Philipp von Gottberg, Dennis Gmehlin, Matthias Backenstraß, Antje Jensch, Elvira Burger-Martin, Olga Grishina, Heidi Fricker, Natalie Malenica, András Orbán, Justus Duyster, Gabriele Ihorst, Juergen Finke, Gerald Illerhaus
Journal: The Lancet Haematology (2024)
Impact of HIV self-testing for oral pre-exposure prophylaxis scale-up on drug resistance and HIV outcomes in western Kenya: a modelling study
Authors: Sarah N Cox, Linxuan Wu, Rachel Wittenauer, Samantha Clark, D Allen Roberts, Ifechukwu Benedict Nwogu, Olga Vitruk, Alexandra P Kuo, Cheryl Johnson, Muhammad S Jamil, Anita Sands, Robin Schaefer, Christine Kisia, Rachel Baggaley, Joanne D Stekler, Adam Akullian, Monisha Sharma
Journal: The Lancet HIV (2024)

BackgroundCommunity-based oral pre-exposure prophylaxis (PrEP) provision has the potential to expand PrEP coverage. HIV self-testing can facilitate PrEP community-based delivery but might have lower sensitivity than facility-based HIV testing, potentially leading to inappropriate PrEP use among people with HIV and subsequent development of drug resistance. We aimed to evaluate the impact of HIV self-testing use for PrEP scale-up.MethodsWe parameterised an agent-based network model, EMOD-HIV, to simulate generic tenofovir disoproxil fumarate and emtricitabine PrEP scale-up in western Kenya using four testing scenarios: provider-administered nucleic acid testing, provider-administered rapid diagnostic tests detecting antibodies, blood-based HIV self-testing, or oral fluid HIV self-testing. Scenarios were compared with a no PrEP counterfactual. Individuals aged 18–49 years with one or more heterosexual partners who screened HIV-negative were eligible for PrEP. We assessed the cost and health impact of rapid PrEP scale-up with high coverage over 20 years, and the budget impact over 5 years, using various HIV testing modalities.FindingsPrEP coverage of 29% was projected to avert approximately 54% of HIV infections and 17% of HIV-related deaths among adults aged 18–49 years over 20 years; health impacts were similar across HIV testing modalities used to deliver PrEP. The percentage of HIV infections with PrEP-associated nucleoside reverse transcriptase inhibitor (NRTI) drug resistance was 0·6% (95% uncertainty intervals 0·4–0·9) in the blood HIV self-testing scenario and 0·8% (0·6–1·0) in the oral HIV self-testing scenario, compared with 0·3% (0·2–0·3) in the antibody rapid diagnostic testing scenario and 0·2% (0·1–0·2) in the nucleic acid testing scenario. Accounting for background NRTI resistance, we found similarly low proportions of drug resistance across scenarios. The budget impact of implementing PrEP using HIV self-testing and provider-administered rapid diagnostic tests were similar, while nucleic acid testing was approximately 50% more costly.InterpretationScaling up PrEP using HIV self-testing has similar health impacts, costs, and low risk of drug resistance as provider-administered rapid diagnostic tests. Policy makers should consider leveraging HIV self-testing to expand PrEP access among those at HIV risk.FundingThe Bill and Melinda Gates Foundation.
Covered versus bare-metal stenting of the mesenteric arteries in patients with chronic mesenteric ischaemia (CoBaGI): a multicentre, patient-blinded and investigator-blinded, randomised controlled trial
Authors: Luke G Terlouw, Louisa J D van Dijk, Desirée van Noord, Olaf J Bakker, Diederik C Bijdevaate, Nicole S Erler, Bram Fioole, Jihan Harki, Daniel A F van den Heuvel, Jan Willem Hinnen, Jeroen J Kolkman, Suzan Nikkessen, André S van Petersen, Henk F M Smits, Hence J M Verhagen, Annemarie C de Vries, Jean-Paul P M de Vries, Dammis Vroegindeweij, Robert H Geelkerken, Marco J Bruno, Adriaan Moelker, Ron Balm, Olaf J Bakker, Diederik C Bijdevaate, Juliette T Blauw, Gert Jan de Borst, Philip R Bos, Marco J Bruno, Hessel C J L Buscher, Louisa J D van Dijk, Annet A M van Duivenvoorden, Nicole S Erler, Bram Fioole, Robert H Geelkerken, Jaap F Hamming, Jihan Harki, Duygu Harmankaya, Eline S van Hattum, Daniel A F van den Heuvel, Jan Willem Hinnen, Jeroen J Kolkman, Maarten J van der Laan, Kaatje Lenaerts, Tim Lubbers, Mark van der Lugt, Floor M Metz, Adriaan Moelker, Suzan Nikkessen, Derirée van Noord, Kaushal Parikh, Peter J van der Schaar, Henk F M Smits, Luke G Terlouw, Hence J M Verhagen, Annemarie C de Vries, Jean Paul P M de Vries, Dammis Vroegindeweij, Gijs M J M Welten
Journal: The Lancet. Gastroenterology & hepatology (2024)
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial
Authors: Adrie Bekker, Nicolas Salvadori, Helena Rabie, Samantha du Toit, Kanchana Than-in-at, Marisa Groenewald, Ratchada Cressey, James Nielsen, Edmund V Capparelli, Marc Lallemant, Mark F Cotton, Tim R Cressey
Journal: The Lancet HIV (2024)
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
Authors: Ken K Y Ho, Maria Fleseriu, John Wass, Laurence Katznelson, Gerald Raverot, Andrew S Little, Justo P Castaño, Martin Reincke, M Beatriz Lopes, Ursula B Kaiser, Philippe Chanson, Mônica Gadelha, Shlomo Melmed
Journal: The Lancet Diabetes & Endocrinology (2024)
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial
Authors: Eliza F Chakravarty, Tammy Utset, Diane L Kamen, Gabriel Contreras, W Joseph McCune, Cynthia Aranow, Kenneth Kalunian, Elena Massarotti, Megan E B Clowse, Brad H Rovin, S Sam Lim, Vikas Majithia, Maria Dall'Era, R John Looney, Doruk Erkan, Amit Saxena, Nancy J Olsen, Kichul Ko, Joel M Guthridge, Ellen Goldmuntz, Jessica Springer, Carla D'Aveta, Lynette Keyes-Elstein, Bill Barry, Ashley Pinckney, James McNamara, Judith A James
Journal: The Lancet Rheumatology (2024)
The effect of nutrition-specific and nutrition-sensitive interventions on the double burden of malnutrition in low-income and middle-income countries: a systematic review
Authors: Nora A Escher, Giovanna C Andrade, Suparna Ghosh-Jerath, Christopher Millett, Paraskevi Seferidi
Journal: The Lancet Global Health (2024)

BackgroundLow-income and middle-income countries (LMICs) experiencing nutrition transition face an increasing double burden of malnutrition (DBM). WHO has urged the identification of risks and opportunities in nutrition interventions to mitigate the DBM, but robust evidence is missing. This review summarises the effect of nutrition-specific and nutrition-sensitive interventions on undernutrition and overnutrition in LMICs.MethodsWe searched four major databases and grey literature for publications in English, French, Portuguese, and Spanish from Jan 1, 2000, to Aug 14, 2023. Eligible studies evaluated nutrition-specific or nutrition-sensitive interventions on both undernutrition and overnutrition, employing robust study designs (individually randomised, cluster randomised, and non-randomised trials; interrupted time series; controlled before–after; and prospective cohort studies). Studies were synthesised narratively, and classified as DBM-beneficial, potentially DBM-beneficial, DBM-neutral, potentially DBM-harmful, and DBM-harmful, using vote counting. This review is registered with PROSPERO (CRD42022320131).FindingsWe identified 26 studies evaluating 20 nutrition-specific (maternal and child health [MCH] and school-based programmes) and six nutrition-sensitive (conditional cash transfers and other social policies) interventions. Seven of eight MCH interventions providing food-based or nutritional supplements indicated possible DBM-harmful effects, associated with increased maternal or child overweight. Most school-based programmes and MCH interventions that target behavioural change were considered potentially DBM-beneficial. Two studies of conditional cash transfers suggested DBM-beneficial effects in children, whereas one indicated potentially harmful effects on maternal overweight. A study on a family planning service and one on an education reform revealed possible long-term harmful effects on obesity.InterpretationThere is considerable scope to repurpose existing nutrition interventions to reduce the growing burden of the DBM in LMICs. In settings undergoing rapid nutrition transition, specific policy attention is required to ensure that food-based or supplement-based MCH programmes do not unintentionally increase maternal or child overweight. Consistent reporting of undernutrition and overnutrition outcomes in all nutrition interventions is essential to expand the evidence base to identify and promote interventions maximising benefits and minimising harms on the DBM.FundingPresident's Scholarship (Imperial College London) and National Institute for Health and Care Research.TranslationsFor the Portuguese, Spanish and French translations of the abstract see Supplementary Materials section.
Correction to Lancet Oncol 2023; 24: 1018–28
Journal: The Lancet Oncology (2024)

In this Article, the first sentence in the Introduction should read "Isocitrate dehydrogenase 1 (IDH1) mutations are detected in approximately 13% (range 9-20%)…" This correction has been made to the online version as of January 29, 2024.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Authors: Icro Meattini, Carlotta Becherini, Saverio Caini, Charlotte E Coles, Javier Cortes, Giuseppe Curigliano, Evandro de Azambuja, Clare M Isacke, Nadia Harbeck, Orit Kaidar-Person, Elisabetta Marangoni, Birgitte V Offersen, Hope S Rugo, Viola Salvestrini, Luca Visani, Andrea Morandi, Matteo Lambertini, Philip Poortmans, Lorenzo Livi, Sara Alkner, Indrani S. Bhattacharya, Liesbeth Boersma, Maurizio Callari, Robert B. Clarke, Lucia Del Mastro, Maria Ekholm, Alessandra Gennari, Anna M. Kirby, Stephanie Kroeze, Marcos Malumbres, Maja Vestmø Maraldo, Gustavo Nader Marta, Ingvil Mjaaland, Gilberto Morgan, Barbara Pistilli, Shani Paluch-Shimon, Sofia Rivera, Sven Rottenberg, Cristina Saura, Tanja Skyttä, Tanja Spanic
Journal: The Lancet Oncology (2024)
Current and projected gaps in the availability of radiotherapy in the Asia-Pacific region: a country income-group analysis
Authors: Dania Abu Awwad, Jesmin Shafiq, Geoffrey Paul Delaney, Yavuz Anacak, Freddie Bray, Jerickson Abbie Flores, Soehartati Gondhowiardjo, Minjmaa Minjgee, Tiara Bunga Mayang Permata, Jaffar C Pineda, Suhana Yusak, Eduardo Zubizarreta, Mei Ling Yap
Journal: The Lancet Oncology (2024)
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study
Authors: Megan McLeod, Julie Torode, Kari Leung, Nirmala Bhoo-Pathy, Christopher Booth, Jade Chakowa, Julie Gralow, Andre Ilbawi, Jacek Jassem, Jeannette Parkes, Merixtell Mallafré-Larrosa, Miriam Mutebi, CS Pramesh, Manju Sengar, Audrey Tsunoda, Karla Unger-Saldaña, Verna Vanderpuye, Aasim Yusuf, Richard Sullivan, Ajay Aggarwal
Journal: The Lancet Oncology (2024)